INTERVIEW: SillaJen CEO Confident On ‘Dream’ Cancer Therapy (Pt. 2)
This article was originally published in PharmAsia News
Executive Summary
After years of convincing the medical industry about the value of its novel cancer immunotherapy, South Korea’s SillaJen may be stepping closer to its goal of commercializing the “dream cancer therapy.” The bioventure’s CEO, Moon Eun-sang, shares his views on the product and SillaJen’s future in this second and final part of an exclusive interview with PharmAsia News.